Mutated DNMT3A creates a public HLADQ- binding neoantigen on acute myeloid leukemia
We here identified a public HLA class II-restricted neoantigen encoded by a driver mutation occurring in 10% of patients with AML that could become an important target for immunotherapy to treat patients with <i>DNMT3A-R882H</i>-mutated AML.
Authors
- Marieke Griffioen (ORCID: https://orcid.org/0000-0002-3001-4441)
- Rob C. M. de Jong
- Nadine E. Struckman
- Dyantha I. van der Lee (ORCID: https://orcid.org/0000-0002-0369-3856)
- J.H. Frederik Falkenburg (ORCID: https://orcid.org/0000-0002-9819-4813)
- Eva M. Argiro (ORCID: https://orcid.org/0009-0006-7006-2751)
- M. Willy Honders
- Sebastiaan N. J. Laan
Institutions
- Leiden University Medical Center (NL)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-13
- DOI
- https://doi.org/10.3389/fimmu.2025.1556121
- Citations
- 3
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.14